Episode Summary
Executive Summary: Peter Attia opens by explaining the podcast’s listener-supported model and then interviews Dr. Deborah Kimlis and Steve Goldner about cannabis, THC, CBD, hemp, safety, and regulation. The discussion covers cannabinoid biology, historical use, hemp’s legal status, vaping risks, dosing/route differences, therapeutic potential, and the need for standardized research and federal reform.
Main Topics: Why the podcast is listener-supported (Priority: 3/5): Attia explains why he avoids ads: trust, authenticity, and a desire to keep the relationship with listeners simple while offering members extra content and deals. Cannabis basics: THC, CBD, receptors, and mechanisms (Priority: 5/5): The guests distinguish THC from CBD, explain CB1/CB2 receptors, and emphasize cannabis as a multimodal botanical medicine rather than a single-target drug. History, prohibition, and hemp legalization (Priority: 4/5): They trace cannabis use back thousands of years, discuss prohibition and the war on drugs, and explain how the Farm Bill enabled hemp cultivation and commercialization. Safety, toxicity, and vaping concerns (Priority: 5/5): The conversation contrasts cannabis with alcohol and opioids, argues cannabinoids have a wide therapeutic window, and reviews the 2019 vaping-associated lung injury outbreak as likely tied to additives and poor regulation. Routes of administration and dosing consistency (Priority: 5/5): They compare smoking, vaping, edibles, and sublingual water-soluble tablets, stressing that inhalation is fast but hard to dose, while edibles are variable and sublingual delivery may be more precise. Clinical use, evidence, and research limitations (Priority: 5/5): The guests describe small pilot studies, anecdotal outcomes, and the difficulty of doing rigorous trials because of federal restrictions, university risk aversion, and inconsistent state rules. Business, regulation, and future federal reform (Priority: 4/5): They discuss their company’s Michigan-only operations, GMP standards, IND filings, and the belief that federal descheduling/legal reform is necessary for standardized testing, research, and interstate commerce.
Key Arguments: Cannabis should be understood as a complex botanical medicine with over 100 cannabinoids and many terpenes, not just THC or CBD. THC acts mainly through CB1 and CB2 receptors and can affect pain, appetite, memory, and nausea, but effects vary widely by person and dose. CBD is non-intoxicating, works indirectly through the endocannabinoid system and other pathways, and may help pain, sleep, and anxiety. Cannabis has a very wide therapeutic window and far lower acute lethality than opioids or alcohol; overdose deaths from cannabinoids are not a major concern. The 2019 vaping crisis likely reflects unsafe additives, poor manufacturing, and lack of oversight rather than cannabis itself. Smoking and vaping are difficult to standardize; sublingual water-soluble formulations may offer faster, more reliable dosing without first-pass metabolism. Edibles are highly variable because heating, digestion, and metabolism change the active compounds and their potency. Cannabis is not supported by strong evidence as a gateway drug; the guests argue it may be more of an exit drug for some people reducing opioid use. Federal illegality blocks robust research, standardized testing, and interstate commerce, leaving states with uneven rules and consumers with inconsistent product quality. The guests argue that patients should buy from legal dispensaries, request certificates of analysis, and avoid unregulated online or street products.
Data Points: Historical use: Over 5,000 years - Cannabis described as having medicinal use for millennia. Patient cohort in pilot CBD pain study: 16 patients - Dr. Kimlis described a proof-of-concept trial of water-soluble CBD for mild to moderate pain. Pain study duration: 2 weeks - The pilot trial ran for two weeks. Pain study outcome: Statistically significant decrease in pain - Reported across all 16 patients in the pilot study. CBD dose in pilot formulation: 5 mg - Ultra-low-dose CBD tablet used in the pain proof-of-concept study. Michigan medical marijuana cardholders: Over 400,000 - Used to illustrate the scale of medical cannabis use in Michigan. Dispensary users seeking medical reasons: Two-thirds - Dr. Kimlis said most dispensary users in her survey were there for medical reasons, not intoxication. Cannabis therapeutic index: 1:20,000 to 1:40,000 - Steve Goldner contrasted cannabis safety with narrower therapeutic-index drugs. Alcohol therapeutic index: About 1:10 - Used as a comparison to show alcohol’s narrower safety margin. THC lethal dose: No practical LD50 established; cited as >5 g/kg - They argued it is extremely difficult to reach a lethal dose with cannabinoids. DEA attorney estimate of fatal smoking amount: 1,500 pounds of cannabis flower in 15 minutes - Cited to illustrate the implausibility of lethal cannabis overdose by smoking. Reported vaping deaths at time of recording: Over 34 deaths - Discussed as part of the 2019 vaping-associated lung injury outbreak. Hospitalizations from vaping outbreak: Hundreds to thousands - Described as a growing public health issue. CBD sleep pharmacovigilance: Several hundred thousand people - Goldner claimed post-market experience suggesting CBD helps sleep without grogginess. Average cannabis use in Dutch medical program: 750 mg/day - Mentioned as a data point suggesting limited tachyphylaxis in one medical program. Company workforce: About 100 employees - Goldner described the size of the company’s operational team. Research support team: About 10 direct people plus 30-40 consultants - Described the broader research infrastructure around the company. Plants under cultivation: About 5,500 plants - Michigan cultivation and processing operations. Dispensary relationships: 70-80 dispensary stores - Distribution network within Michigan. INDs filed: 3 filed - Goldner said the company had three investigational new drug filings underway. Drug development timeline: About 10 years and $1 billion - Used to explain why bringing a new drug to market is difficult and expensive. Fast-track approval estimate: 2-4 years - Goldner suggested some indications might move faster through FDA pathways.
Pivotal Quotes: "I have a really hard time advocating for something that I'm not absolutely nuts for." — Peter Atiyah: Explaining why he avoids ad sponsorships and prefers listener support. "Cannabis is a gateway more towards health than to other drugs." — Dr. Deborah Kimlis: Her response to the gateway-drug debate and cannabis’s potential role in reducing harm. "The therapeutic index for cannabis... is one to 20,000 to one to 40,000." — Steve Goldner: Used to argue that cannabinoids have a very wide safety margin compared with many drugs.
Implications: The episode argues for standardized, federally enabled cannabis research and regulation. For listeners, it offers practical caution: buy tested products, avoid unregulated vapes, and recognize that route, dose, and formulation matter as much as the molecule.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.